Market Research Report

Global Kidney/Renal Fibrosis Treatment Market Report By Type Therapeutics (Angiotensin II Receptor Blockers (ARBs), Angiotensin Converting Enzyme (ACE) Inhibitors, Pirfenidone, Renin Inhibitors, and Vasopeptidase Inhibitors), By Diagnostic Center (Hospital Testing, Commercial/Private Hospitals, Public Health Hospitals, Clinics, and Home Treatment) And By Regions - Industry Trends, Size, Share, Growth, Estimation and Forecast, 2021-2028

ID:VMR11210051
April 2021
Report Formats: Electronic (PDF), MS EXCEL

In the current scenario, the Kidney/Renal Fibrosis Treatment market is an extremely beneficial commercial segment due to the growing number of patients suffering from various types CKD and renal fibrosis. Moreover, increasing government support for developing novel therapies and rising investment in R&D on developing personalized medicine in various private and the public hospital is further propelling the market growth. The advent of the promising drug in the market coupled with the increasing medical expenditure and growing medical tourism rate is another major factor pushing the market growth uphill. Additionally, various recent technological breakthrough such as point-of-care drug delivery systems and penetration of personalized drug is likely to offer opportunity growth to the market over the forecast period.

As per Value Market Report, Kidney/Renal Fibrosis Market is expected to be worth USD 10,486.5 MN by 2024 with a CAGR of 3.5%.
 
ANGIOTENSIN-CONVERTING ENZYME (ACE) TO LEAD THE SEGMENT
It is estimated that ACE Inhibitors will touch USD 3,735.7 MN by end of 2024. The ACE inhibitor is dominating the segment owing to the rising application of a various disorder such as heart, blood vessel, and kidney problems. Basically, this group of drugs causes relaxation of blood vessels as well as a decrease in blood volume, which resulted in lower blood pressure and decreased oxygen demand from the heart. They curb the growth of angiotensin-converting enzyme, an important component of the renin-angiotensin system. Henceforth, this segment is likely to grow on the ground of rising prevalence of various renal disinfections along with the growing population base across the globe.
 
HOSPITAL TESTING TO GAIN THE TRACTION
The hospital testing is accounted for the largest market in 2017. The hospital testing is leading the segment owing to the growing investment in R&D on developing personalized medicine in various private and the public hospital. Also, the rising number of the hospital along with growing healthcare expenditure is another major factor in boosting the growth of the segment.
 
NORTH AMERICA EMERGED AS THE LARGEST MARKET FOR KIDNEY FIBROSIS
North America is accounted for the largest market for kidney fibrosis treatment owing to the presence of a large base of patients suffering from chronic kidney disease (CKD).  Major driving factors raising the growth of this market are the growing base of the population suffering from chronic kidney diseases and high incidence rate of renal fibrosis among the population. Moreover, the development of safe and effective therapeutics for the treatment of kidney fibrosis is contributing to the growth of the regional market.
 
THIS REPORT INCLUDES KEY PLAYERS ALONG WITH THEIR MARKET SHARE
Galectin Therapeutics, Merck & Co., F. Hoffman-La Roche Ltd., Pfizer Inc., InterMune Inc., ProMetic Life-Sciences Inc., La Jolla Pharmaceutical Company, Genzyme Corporation, and BioLine Rx Ltd

As per this study the global kidney/renal fibrosis treatment market was valued USD XX MN (by revenue) in 2021 and is anticipated to reach USD XX MN by 2028 with a CAGR of XX%.
 
Technically, fibrosis is a biological process which leads to the formation of access fibrous connective tissue in an organ/tissue in a repetitive way. Fibrosis can be a volatile, benign, or pathological state. In response to injury, this is called scarring, and if fibrosis rises from a single cell line, this is called a fibroma. Basically, it is related to the process of scarring. The process is initiated when immune cells such as macrophages release soluble factors that stimulate fibroblasts. Kidney/renal fibrosis may be caused due to disease/infection in the kidney.
 
Market Dynamics
 
The kidney/renal fibrosis treatment market is a highly beneficial market owing to the increasing base of a population suffering from chronic kidney diseases and renal fibrosis. Moreover, increasing government support for developing novel therapies and rising investment in R&D on developing personalized medicine in various private and the public hospital is further propelling the market growth. On the flip side, strict regulatory approvals related to kidney fibrosis therapeutics may limit the market growth.
 
This detailed market study is centered on the data obtained from multiple sources and is analyzed using numerous tools including porter’s five forces analysis, market attractiveness analysis and value chain analysis. These tools are employed to gain insights of the potential value of the market facilitating the business strategists with the latest growth opportunities. Additionally, these tools also provide a detailed analysis of each application/product segment in the global market of kidney/renal fibrosis treatment.
 
Market Segmentation
 
The broad kidney/renal fibrosis treatment market has been sub-grouped into therapeutics, and diagnostic center. The report studies these subsets with respect to the geographical segmentation. The strategists can gain a detailed insight and devise appropriate strategies to target specific market. This detail will lead to a focused approach leading to identification of better opportunities.
  
By Therapeutics
  • Angiotensin II Receptor Blockers (ARBs)
  • Angiotensin Converting Enzyme (ACE) Inhibitors
  • Pirfenidone
  • Renin Inhibitors
  • Vasopeptidase Inhibitors
 
By Diagnostic Center
  • Hospital Testing
  • Commercial/Private Hospitals
  • Public Health Hospitals
  • Clinics
  • Home Treatment
 
Regional Analysis
 
Furthermore, the report comprises of the geographical segmentation which mainly focuses on current and forecast demand for kidney/renal fibrosis treatment in North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The report further focuses on demand for individual application segments in all the regions.
 
Global Kidney/Renal Fibrosis Treatment Market Share by Region (Representative Graph)
 
Global Kidney/Renal Fibrosis Treatment Market Share
 
The report also covers detailed competitive landscape including company profiles of key players operating in the global market. The key players in the kidney/renal fibrosis treatment market includes Merck & Co., F. Hoffman-La Roche Ltd., Pfizer Inc., Galectin Therapeutics, La Jolla Pharmaceutical Company, InterMune Inc., ProMetic Life-Sciences Inc., Genzyme Corporation, and BioLine Rx Ltd. An in-depth view of the competitive outlook includes future capacities, key mergers & acquisitions, financial overview, partnerships, collaborations, new product launches, new product developments and other developments with information in terms of H.Q.
 
METHODOLOGY:
 
A combination of primary and secondary research has been used to determine the market estimates and forecasts. Sources used for secondary research include (but not limited to) Paid Data Sources, Company Websites, Technical Journals, Annual Reports, SEC Filings and various other industry publications. Specific details on methodology used for this report can be provided on demand. 

1 . PREFACE
       1.1. Report Description
           1.1.1. Objective
           1.1.2. Target Audience
           1.1.3. Unique Selling Proposition (USP) & offerings
       1.2. Research Scope
       1.3. Research Methodology
           1.3.1. Market Research Process
           1.3.2. Market Research Methodology
 
2 . EXECUTIVE SUMMARY
       2.1. Highlights of Market
       2.2. Global Market Snapshot
 
3 . KIDNEY/RENAL FIBROSIS TREATMENT – INDUSTRY ANALYSIS
       3.1. Introduction - Market Dynamics
       3.2. Market Drivers
       3.3. Market Restraints
       3.4. Opportunities
       3.5. Industry Trends
       3.6. Porter’s Five Force Analysis
       3.7. Market Attractiveness Analysis
           3.7.1 Market Attractiveness Analysis By Therapeutics
           3.7.2 Market Attractiveness Analysis By Diagnostic Center
           3.7.3 Market Attractiveness Analysis By Region
 
4 . VALUE CHAIN ANALYSIS
       4.1. Value Chain Analysis
       4.2. Raw Material Analysis
           4.2.1. List of Raw Materials
           4.2.2. Raw Material Manufactures List
           4.2.3. Price Trend of Key Raw Materials
       4.3. List of Potential Buyers
       4.4. Marketing Channel
           4.4.1. Direct Marketing
           4.4.2. Indirect Marketing
           4.4.3. Marketing Channel Development Trend
 
5 . IMPACT ANALYSIS OF COVID-19 OUTBREAK
       5.1. Impact Analysis of Covid-19 Outbreak
           5.1.1. Direct Impact on Production
           5.1.2. Supply Chain and Market Disruption
           5.1.3. Financial Impact on Firms and Financial Markets
       5.2. COVID-19 Impact Analysis by Production, Import, Export and Demand
       5.3. Market: Pre V/S Post COVID-19
       5.4. Estimated Impact of the Coronavirus (COVID-19) Epidemic 
       5.5. COVID-19: Micro and Macro Factor Analysis
 
6 . GLOBAL KIDNEY/RENAL FIBROSIS TREATMENT MARKET ANALYSIS BY THERAPEUTICS
       6.1 Overview by Therapeutics
       6.2 Historical and Forecast Data
       6.3 Analysis by Therapeutics
       6.4 Angiotensin II Receptor Blockers (ARBs) Historic and Forecast Sales by Regions
       6.6 Angiotensin Converting Enzyme (ACE) Inhibitors Historic and Forecast Sales by Regions
       6.5 Pirfenidone Historic and Forecast Sales by Regions
       6.7 Renin Inhibitors Historic and Forecast Sales by Regions
       6.8 Vasopeptidase Inhibitors Historic and Forecast Sales by Regions
 
7 . GLOBAL KIDNEY/RENAL FIBROSIS TREATMENT MARKET ANALYSIS BY DIAGNOSTIC CENTER
       7.1 Overview by Diagnostic Center
       7.2 Historical and Forecast Data
       7.3 Analysis by Diagnostic Center
       7.4 Hospital Testing Historic and Forecast Sales by Regions
       7.5 Commercial/Private Hospitals Historic and Forecast Sales by Regions
       7.6 Public Health Hospitals Historic and Forecast Sales by Regions
       7.7 Clinics Historic and Forecast Sales by Regions
       7.8 Home Treatment Historic and Forecast Sales by Regions
 
8 . GLOBAL KIDNEY/RENAL FIBROSIS TREATMENT MARKET ANALYSIS BY GEOGRAPHY
       8.1. Regional Outlook
       8.2. Introduction
       8.3. North America Sales Analysis
           8.3.1. Overview, Historic and Forecast Sales Analysis
           8.3.2. North America By Segment Sales Analysis
           8.3.3. North America By Country Sales Analysis
           8.3.4. United State Sales Analysis
           8.3.5. Canada Sales Analysis
           8.3.6. Mexico Sales Analysis
       8.4. Europe Sales Analysis
           8.4.1. Overview, Historic and Forecast Sales Analysis
           8.4.2. Europe by Segment Sales Analysis
           8.4.3. Europe by Country Sales Analysis
           8.4.4. United Kingdom Sales Analysis
           8.4.5. France Sales Analysis
           8.4.6. Germany Sales Analysis
           8.4.7. Italy Sales Analysis
           8.4.8. Russia Sales Analysis
           8.4.9. Rest Of Europe Sales Analysis
       8.5. Asia Pacific Sales Analysis
           8.5.1. Overview, Historic and Forecast Sales Analysis
           8.5.2. Asia Pacific by Segment Sales Analysis
           8.5.3. Asia Pacific by Country Sales Analysis
           8.5.4. China Sales Analysis
           8.5.5. India Sales Analysis
           8.5.6. Japan Sales Analysis
           8.5.7. South Korea Sales Analysis
           8.5.8. Australia Sales Analysis
           8.5.9. Rest Of Asia Pacific Sales Analysis
       8.6. Latin America Sales Analysis
           8.6.1. Overview, Historic and Forecast Sales Analysis
           8.6.2. Latin America by Segment Sales Analysis
           8.6.3. Latin America by Country Sales Analysis
           8.6.4. Brazil Sales Analysis
           8.6.5. Argentina Sales Analysis
           8.6.6. Peru Sales Analysis
           8.6.7. Chile Sales Analysis
           8.6.8. Rest of Latin America Sales Analysis
       8.7. Middle East & Africa Sales Analysis
           8.7.1. Overview, Historic and Forecast Sales Analysis
           8.7.2. Middle East & Africa by Segment Sales Analysis
           8.7.3. Middle East & Africa by Country Sales Analysis
           8.7.4. Saudi Arabia Sales Analysis
           8.7.5. UAE Sales Analysis
           8.7.6. Israel Sales Analysis
           8.7.7. South Africa Sales Analysis
           8.7.8. Rest Of Middle East And Africa Sales Analysis
 
9 . COMPETITIVE LANDSCAPE OF THE KIDNEY/RENAL FIBROSIS TREATMENT COMPANIES
       9.1. Kidney/Renal Fibrosis Treatment Market Competition
       9.2. Partnership/Collaboration/Agreement
       9.3. Merger And Acquisitions
       9.4. New Product Launch
       9.5. Other Developments
 
10 . COMPANY PROFILES OF KIDNEY/RENAL FIBROSIS TREATMENT INDUSTRY
       10.1. Top 10  Company Share Analysis
       10.2. Market Concentration Rate
       10.3. BioLine Rx Ltd.
           10.3.1. Company Overview
           10.3.2. Company Revenue
           10.3.3. Products
           10.3.4. Recent Developments
       10.4. F. Hoffman-La Roche Ltd.
           10.4.1. Company Overview
           10.4.2. Company Revenue
           10.4.3. Products
           10.4.4. Recent Developments
       10.5. Galectin Therapeutics
           10.5.1. Company Overview
           10.5.2. Company Revenue
           10.5.3. Products
           10.5.4. Recent Developments
       10.6. Genzyme Corporation
           10.6.1. Company Overview
           10.6.2. Company Revenue
           10.6.3. Products
           10.6.4. Recent Developments
       10.7. InterMune Inc.
           10.7.1. Company Overview
           10.7.2. Company Revenue
           10.7.3. Products
           10.7.4. Recent Developments
       10.8. La Jolla Pharmaceutical Company
           10.8.1. Company Overview
           10.8.2. Company Revenue
           10.8.3. Products
           10.8.4. Recent Developments
       10.9. Merck & Co.
           10.9.1. Company Overview
           10.9.2. Company Revenue
           10.9.3. Products
           10.9.4. Recent Developments
       10.10. Pfizer Inc.
           10.10.1. Company Overview
           10.10.2. Company Revenue
           10.10.3. Products
           10.10.4. Recent Developments
       10.11. ProMetic Life-Sciences Inc.
           10.11.1. Company Overview
           10.11.2. Company Revenue
           10.11.3. Products
           10.11.4. Recent Developments
 
 *Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies
 
LIST OF TABLES

 

  •  Market Snapshot
  •  Drivers : Impact Analysis
  •  Restraints : Impact Analysis
  •  List of Raw Material
  •  List of Raw Material Manufactures
  •  List of Potential Buyers
  •  COVID-19 Impact Analysis by Production, Import, Export and Demand
  •  Pre V/S Post COVID-19
  •  Estimated Impact Of The Coronavirus (Covid-19) Epidemic
  •  COVID-19: Micro and Macro Factor Analysis
  •  Analysis by Therapeutics (USD MN)
  •  Angiotensin II Receptor Blockers (ARBs) Market Sales by Geography (USD MN)
  •  Angiotensin Converting Enzyme (ACE) Inhibitors Market Sales by Geography (USD MN)
  •  Pirfenidone Market Sales by Geography (USD MN)
  •  Renin Inhibitors Market Sales by Geography (USD MN)
  •  Vasopeptidase Inhibitors Market Sales by Geography (USD MN)
  •  Analysis Market by Diagnostic Center (USD MN)
  •  Hospital Testing Market Sales by Geography (USD MN)
  •  Commercial/Private Hospitals Market Sales by Geography (USD MN)
  •  Public Health Hospitals Market Sales by Geography (USD MN)
  •  Clinics Market Sales by Geography (USD MN)
  •  Home Treatment Market Sales by Geography (USD MN)
  •  Global Kidney/Renal Fibrosis Treatment Market Sales by Geography (USD MN)
  •  North America Market Analysis (USD MN)
  •  United State Market Analysis (USD MN)
  •  Canada Market Analysis (USD MN)
  •  Mexico Market Analysis (USD MN)
  •  Europe Market Analysis (USD MN)
  •  Europe Market Estimate by Country (USD MN)
  •  United Kingdom Market Analysis (USD MN)
  •  France Market Analysis (USD MN)
  •  Germany Market Analysis (USD MN)
  •  Italy Market Analysis (USD MN)
  •  Russia Market Analysis (USD MN)
  •  Spain Market Analysis (USD MN)
  •  Rest of Europe Market Analysis (USD MN)
  •  Asia Pacific Market Analysis (USD MN)
  •  China Market Analysis (USD MN)
  •  Japan Market Analysis (USD MN)
  •  India Market Analysis (USD MN)
  •  South Korea Market Analysis (USD MN)
  •  Australia Market Analysis (USD MN)
  •  Rest of Asia Pacific Market Analysis (USD MN)
  •  Latin America Market Analysis (USD MN)
  •  Brazil Market Analysis (USD MN)
  •  Argentina Market Analysis (USD MN)
  •  Peru Market Analysis (USD MN)
  •  Chile Market Analysis (USD MN)
  •  Rest of Latin America Market Analysis (USD MN)
  •  Middle East & Africa Market Analysis (USD MN)
  •  Saudi Arabia Market Analysis (USD MN)
  •  UAE Market Analysis (USD MN)
  •  Israel Market Analysis (USD MN)
  •  South Africa Market Analysis (USD MN)
  •  Rest of Middle East and Africa Market Analysis (USD MN)
  •  Partnership/Collaboration/Agreement
  •  Mergers And Acquisiton
 
 LIST OF FIGURES
 
  •  Research Scope of Kidney/Renal Fibrosis Treatment Report
  •  Market Research Process
  •  Market Research Methodology
  •  Global Kidney/Renal Fibrosis Treatment Market Size, by Region (USD MN)
  •  Porters Five Forces Analysis
  •  Market Attractiveness Analysis by Therapeutics
  •  Market Attractiveness Analysis by Diagnostic Center
  •  Market Attractiveness Analysis by Region
  •  Value Chain Analysis
  •  Global Market Analysis by Therapeutics (USD MN)
  •  Angiotensin II Receptor Blockers (ARBs) Market Sales by Geography (USD MN)
  •  Angiotensin Converting Enzyme (ACE) Inhibitors Market Sales by Geography (USD MN)
  •  Pirfenidone Market Sales by Geography (USD MN)
  •  Renin Inhibitors Market Sales by Geography (USD MN)
  •  Vasopeptidase Inhibitors Market Sales by Geography (USD MN)
  •  Global Market Analysis by Diagnostic Center (USD MN)
  •  Hospital Testing Market Sales by Geography (USD MN)
  •  Commercial/Private Hospitals Market Sales by Geography (USD MN)
  •  Public Health Hospitals Market Sales by Geography (USD MN)
  •  Clinics Market Sales by Geography (USD MN)
  •  Home Treatment Market Sales by Geography (USD MN)
  •  Global Market by Revenue
  •  North America Market by Revenue
  •  Europe Market by Revenue
  •  Asia Pacific Market by Revenue
  •  Latin America Market by Revenue
  •  Middle East & Africa Market by Revenue
  •  Recent Development in Industry
  •  Top 10  Company Share Analysis
 
 * Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.

Buy Chapters or Sections

Avail customized purchase options to meet your exact research needs:

  • Buy sections of this report
  • Buy country level reports
  • Request for historical data
  • Request discounts available for Start-Ups & Universities

Objectives of Study

  • Define and measure the global market
  • Volume or revenue forecast of the global market and its various sub-segments with respect to main geographies
  • Analyze and identify major market trends along with the factors driving or inhibiting the market growth
  • Study the company profiles of the major market players with their market share
  • Analyze competitive developments

Why Choose Us

Client First Policy
Excellent Quality
After Sales Support
24/7 Email Support

Clients

Testimonials